A rare CRL for $MRK's Keytruda in first-line liver cancer. 

https://t.co/DWxSQdgpRw

In May, FDA OK'd Tecentriq in same setting based , in part, on OS data. 

$MRK's evidence for Keytruda, therefore, was no longer sufficient proof of "meaningful advantage" over existing therapy.